The difference in postoperative survival between NSCLC patients with FOSL2 higher expression and with FOSL2 lower expression was greatly significant ( em P /em ?=?0
The difference in postoperative survival between NSCLC patients with FOSL2 higher expression and with FOSL2 lower expression was greatly significant ( em P /em ?=?0.0059 by log-rank test). Discussion Our results demonstrate that FOSL2 up-regulation is necessary for TGF-1-induced migration. FOSL2 promotes P300 binding to Smad3 and the acetylation of Smad3 by P300. Furthermore, we show that the expression of FOSL2 correlates with activated Smad3 expression in clinical non-small cell lung cancer (NSCLC) samples. In summary, the present study indicates that FOSL2 facilitates TGF-1-induced migration by interaction with Smad3 in NSCLC and suggests FOSL2 as a potential therapeutic target for NSCLC. Introduction The TGF- pathway controls diverse biological processes, Pyraclonil including cell proliferation, differentiation, apoptosis, and migration [1]. Following the activation of heteromeric type II and Pyraclonil type I serine-threonine kinase receptor complexes upon TGF- ligand binding, intracellular signalling is initiated by phosphorylation of receptor activated Smad proteins (R-Smads) [2]. As transcriptional factors of the TGF- Rabbit polyclonal to cyclinA pathway, phosphorylated Smad2/3 forms a complex with Smad4 and then translocates to the nucleus to regulate the transcription of TGF- pathway target genes [3]. Cellular responses to TGF- signalling are further influenced by the interaction of Smad proteins with cofactors (coactivators or corepressors) to modulate transcriptional activity [4]. Fos-related antigen 2 (FRA-2/FOSL2) belongs to the AP-1 transcription factor family, which includes the various isoforms of Fos and Jun [5]. The various FOS proteins play key roles in distinct developmental, physiological, and pathological processes [6], but these individual roles and the mechanisms involved are not yet clear. FOSL2 exerts a specific function in bone development [7] and appears to have selective physiological and pathological roles in diverse processes, including photoperiodic regulation [8], cancer [9], and fibrosis [10]. Several previous studies have indicated that FOSL2 plays a key role in the regulation of TGF- pathway. For example, FOSL2 is overexpressed in systemic sclerosis (SSc) and acts as a novel downstream mediator of the profibrotic cytokine TGF- [11]. In cardiac fibroblasts, FOSL2 as a transcriptional regulator may induce TGF- expression [10]. Moreover, FOSL2 is necessary for TGF–induced lysyl oxidase-like 4 (LOXL4) expressions in the regulation of extracellular Pyraclonil matrix (ECM) synthesis and remodeling [12]. However, it is unknown whether FOSL2 regulates TGF- pathway in carcinogenesis. The present study was initiated to examine the role of FOSL2 in TGF–induced migration. The expression of FOSL2 was increased following TGF- treatment and was required for TGF-1-induced migration. FOSL2 was also shown to bind to Smad3 to modulate TGF–induced signalling responses. Materials and Methods Ethics Statement Patient information and samples were obtained with written informed consent. Each Pyraclonil patient in this study gave written informed consent to publish these case details. The research was approved by the ethics committee of Harbin Medical University Cancer Hospital. Cell Lines, Cell Culture, and Transfection The human lung adenocarcinoma cell line A549 and human embryonic kidney cell line 293T were purchased from American Type Culture Collection (ATCC) and maintained in DMEM supplemented with 10% foetal bovine serum (FBS) (Invitrogen) containing 100 units/ml penicillin and 100 units/ml streptomycin (Sigma) at 37C with 5% CO2. For induction of EMT, A549 cells were cultured in 10% FBS for 24 hours and then maintained for 72 hours in serum-free medium in the presence of 2 ng/ml of TGF-1 (R&D Systems). A549 cells were transfected using X-tremeGENE (Roche Applied Science), and HEK293T cells were transfected using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s directions. A small interfering RNA (siRNA) targeting human FOSL2 was transfected into cells for 24 hours using Lipofectamine RNAiMAX Reagent (Invitrogen). Plasmids and Antibodies Myc-tagged Smad3, FLAG-tagged FOSL2, and HA-tagged p300 were constructed by standard subcloning. Full-length Smad3 was subcloned in-frame to the pGEX4T-1 vector to obtain GST fusion proteins. The 3TP-lux reporter plasmid was obtained from Dr Joan Massague of Sloan- Kettering Institute, New York, NY. Antibodies were purchased as follows: anti-FOSL2, anti-FLAG, anti-Myc, anti-HA, and anti-GAPDH from Sigma; anti-p300, anti-Smad3, and anti-GST from Santa Cruz; anti-acetylated-lysine from Cell Signaling Technology; anti-p-smad3 from Abcam; Alexa Fluor 488 donkey anti-mouse IgG and Alexa Fluor 546 donkey anti-rabbit IgG from Invitrogen. siRNAs for FOSL2 and the negative control were obtained from Dharmacon. Immunoprecipitation and Western Blotting Analysis.